Sanofi will eliminate 229 positions in Massachusetts.
The move follows the company's $9.1 billion acquisition of Blueprint Medicines.
The layoffs impact former staff at Blueprint Medicines.
Blueprint Medicines specializes in rare diseases and precision oncology.
Sanofi acquired the firm to bolster its immunology and rare disease portfolio.
The restructuring aims to streamline operations and align the combined entity with long-term business priorities.